logo

CGTX

Cognition·NASDAQ
--
--(--)
--
--(--)

CGTX fundamentals

Cognition (CGTX) released its earnings on Mar 26, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.01 (YoY +94.70%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.01
+94.70%
Report date
Mar 26, 2026
CGTX Earnings Call Summary for Q4,2025
  • DLB Psychosis Priority: Zervimesine targeting unmet need in DLB psychosis with 86% symptom progression reduction in phase II, seeking FDA registrational path.
  • EAP Success: Expanded access program demand highlights real-world impact on patient daily lives.
  • Financial Stability: $37M cash runway through mid-2027, reduced expenses driving 31% net loss improvement.
  • Regulatory Momentum: FDA meetings and EMA alignment to define global trial strategy for DLB psychosis.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Cognition (CGTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cognition (CGTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Cognition (CGTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Cognition (CGTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Cognition (CGTX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Cognition (CGTX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield